A study finds that scientific papers on Alzheimer's disease research conducted in mice are more likely to be covered by the media if they don't mention mice in their titles. This results in exaggerated news headlines and limited reporting of the actual limitations of animal-based research.
Research at Humane Society International found that human organoid models outperform xenografts in predicting patient responses and developing new medicines. Funding for human biology-based approaches remains scarce, highlighting a need to accelerate the transition to more effective non-animal technologies.
Researchers recommend moving away from animal models to in vitro and in silico studies using human-mimetic tools for studying deadly mosquito-borne flaviviruses. The emerging technologies will help predict human pathogenesis and drug efficacy, and improve clinical solutions.
A new study proposes a human-specific understanding of disease mechanisms and novel microphysiological tools to create more predictive laboratory models. This approach holds promise for improving translation in drug discovery and reducing the use of experimental animals.
Researchers advocate for a systems biology approach to better understand Parkinson's disease, emphasizing the need for modern, human-based technologies to improve treatment outcomes.
A Belgian study emphasizes the need for human-based tools in treating non-alcoholic steatohepatitis (NASH), a chronic liver disease impacting millions globally. The study proposes a roadmap to better understand NASH's biological mechanisms, crucial for developing effective treatments.
Scientists in South America are adopting human-specific approaches for biomedical research, utilizing in vitro technologies like iPSCs and organs-on-a-chip. This shift aims to replace animal models, improving health research and developing tailor-made treatments.
A recent international agreement emphasizes the need for human-relevant research in drug discovery, citing a significant decline in successful new drug approvals. The agreement proposes standardized data sharing, consistent ontologies, and prioritization of human-based methods to revitalize the drug development process.